Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: New cases and review of the main dysmorphological findings

Clinical Dysmorphology

Volumn 22, Issue 2, 2013, Pages 59-63

  Vianna, Fernanda S L ^a,b,c,d   Schüler Faccini, Lavínia ^a,b,c,d   Leite, Julio César L ^c   De Sousa, Silvia H C ^e   Da Costa, Lea Márcia M ^f   Dias, Murilo F ^g   Morelo, Elaine F ^h   Doriqui, Maria Juliana R ⁱ   Maximino, Claudia M ^j   Sanseverino, Maria Teresa V ^a,b,c  

^a INAGEMP National Institute of Population Medical Genetics   (Brazil)

^b SIAT Teratogen Information Service   (Brazil)

^c Medical Genetics Service   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e Maternity Dr Benedito Leite and Hospital Juvencio Mattos   (Brazil)

^f State of Maranhão ^*  (Brazil)

^g FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^h MINISTÉRIO DA SAÚDE   (Brazil)

ⁱ Agencia Nacional de Vigilancia Sanitaria Brazil   (Brazil)

^j ABPST   (Brazil)

more..

Author keywords

aberrant tears; embryopathy; heart disease; limb reduction defects; microphthalmia; thalidomide

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN; THALIDOMIDE;

ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; EMBRYOPATHY; ENDEMIC DISEASE; ERYTHEMA NODOSUM LEPROSUM; FEMALE; HUMAN; INFANT; LEPROSY; MALE; MALFORMATION SYNDROME; PHENOTYPE; PRIORITY JOURNAL;

BRAZIL; ENDEMIC DISEASES; ERYTHEMA NODOSUM; FEMALE; FETAL DISEASES; HUMANS; HYPNOTICS AND SEDATIVES; LEGISLATION, DRUG; LEPROSY; MALE; POLYDACTYLY; THALIDOMIDE;

EID: 84874854011     PISSN: 09628827     EISSN: 14735717     Source Type: Journal    
DOI: 10.1097/MCD.0b013e32835ffc58     Document Type: Article

References (20)

1. ANVISA ANdVS (2003). Law 10651/03. Bras?́lia, Brazil: DOU, Diá rio Oficial da Uniã o. Available at: http://pfdc.pgr.mpf.gov. br/atuacao-e-conteudos-deapoio/legislacao/saude/leis/lei-10651-03 [Accessed 4 July 2010].
2. Castilla EE, Ashton-Prolla P, Barreda-Mejia E, Brunoni D, Cavalcanti DP, Correa-Neto J, et al. (1996). Thalidomide, a current teratogen in South America. Teratology 54: 273-277.
3. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085.
4. Düppre NC, Camacho LA, Sales AM, Illarramendi X, Nery JA, Sampaio EP, Sarno EN, Bü hrer-Sé kula S (2012). Impact of PGL-I seropositivity on the protective effect of BCG vaccination among leprosy contacts: a cohort study. PLoS Negl Trop Dis 6: e1711.
5. Gold NB,Westgate MN, Holmes LB (2011). Anatomic and etiological classification of congenital limb deficiencies. Am J Med Genet A 155A: 1225-1235.
6. Kaur I, Dogra S, Narang T, De D (2009). Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study. Australas J Dermatol 50: 181-185.
7. Lenz W (1988). A short history of thalidomide embryopathy. Teratology 38: 203-215.
8. Matthews SJ, McCoy C (2003). Thalidomide: a review of approved and investigational uses. Clin Ther 25: 342-395.
9. Miller MT, Stromland KK (2011).What can we learn from the thalidomide experience: an ophthalmologic perspective. Curr Opin Ophthalmol 22: 356-364.
10. Oliveira MA, Bermudez JAZ, Souza ACM (1999). Talidomida no Brasil: vigilância com responsabilidade compartilhada? Cadernos de Saúde Pública 15: 99-112.
11. Penna GO, Martelli CMT, Stefani MMA, Macedo VO, MdF Maroja, Chaul A (2005). Talidomida no tratamento do eritema nodoso hansê nico: revisão sistemá tica dos ensaios cl?́nicos e perspectivas de novas investigaçõ es. An Bras Dermatol 80: 511-522.
12. Resolution RDC N1-11 (2011). National Health Surveillance Agency of Brazil (ANVISA). Available at: http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/ 2011/res0011-21-03-2011.html.
13. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991). Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173: 699-703.
14. Schmidt M, Salzano FM (1983). Clinical studies on teenage Brazilian victims of thalidomide. Braz J Med Biol Res 16: 105-109.
15. Schuler-Faccini L, Soares RC, de Sousa AC, Maximino C, Luna E, Schwartz IV, Waldman C, Castilla EE (2007). New cases of thalidomide embryopathy in Brazil. Birth Defects Res A Clin Mol Teratol 79: 671-672.
16. Shardein J (1993). Psychotropic drugs. In: Shardein J, editor. Chemically induced birth defects. New York: Marcel Dekker. pp. 208-270.
17. Sheskin J (1965). Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6: 303-306.
18. Sheskin J, Convit J (1969). Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis 37: 135-146.
19. Smithells RW, Newman CG (1992). Recognition of thalidomide defects. J Med Genet 29: 716-723.
20. Vianna F, Lopez-Camelo J, Leite J, Sanseverino MT, MdG Dutra, Castilla EE, et al. (2011). Epidemiological surveillance of birth defects compatible with thalidomide embryopathy in Brazil. Plos One 6: e21735.